AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-06-30

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a dose escalation study to assess the safety and tolerability of AZD0530 in patients with advanced solid malignancies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies

NCT01353781

Advanced Solid Malignancy Advanced Solid Tumor

COMPLETED PHASE1

A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan

NCT00503477

Advanced Solid Tumor

COMPLETED PHASE1

A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies

NCT03980821

Advanced Solid Malignancies

COMPLETED PHASE1

Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient

NCT01213160

Cancer Advanced Solid Malignancies

COMPLETED PHASE1

A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients

NCT00613652

Cancer Tumors Carcinoma

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

AZD0530

Group Type EXPERIMENTAL

AZD0530

Intervention Type DRUG

oral, tablet, once daily, dose will be variable

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD0530

oral, tablet, once daily, dose will be variable

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically confirmed advanced carcinoma / solid tumour of known primary site, which is refractory to standard therapies or for which no standard therapy exists
* World Health Organisation (WHO) performance status 0 to 2
* Life expectancy of at least 12 weeks